Jump to Main Contents
ncc en

Annual Report 2021

Rare Cancer Center

(Tsukiji Campus) Akira Kawai, Yoko Katoh, Ayumu Arakawa, Hiroshi Igaki, Mituya Ishikawa, Koji Izutsu, Shintaro Iwata, Chitose Ogawa, Takuji Okusaka, Tomoyasu Kato, Shingo Kawaguchi, Yasushi Goto, Eisuke Kobayashi, Motokiyo Komiyama, Tadashi Kondo, Takuro Sakurai, Taro Shibata, Toshio Shimizu, Tatsunori Shimoi, Shigenobu Suzuki, Tatsuya Suzuki, Kazuki Sudo, Miyuki Sone, Tomoko Takayama, Kenjiro Namikawa, Yoshitaka Narita, Takahiro Higashi, Susumu Hijioka, Yoshitaka Honma, Aiko Maejima, Yasuji Miyakita, Wataru Munakata, Chigusa Morizane, Naoya Yamazaki, Noboru Yamamoto, Akihiko Yoshida, Seiichi Yoshimoto, Kan Yonemori
(Kashiwa Campus) Tetsuo Akimoto, Junya Ueno, Naoto Gotohda, Toshihiko Doi, Yoichi Naito, Ako Hosono

Introduction

 The Rare Cancer Center, which was established in June 2014 and comprises expert health care providers from various units, provides state-of-the-art, optimal medical care for rare cancers. It also promotes cutting-edge research and treatment development, and clarifies and addresses issues in medical care for rare cancers through medical care and research. The Rare Cancer Center plays an important role in measures against rare cancers not only in the National Cancer Center but also all over Japan. The National Institute for Rare Cancers in Japan was assigned to the National Cancer Center in April 2018. Rare cancers are defined as those with an incidence < 6/100,000/year. Although each subtype of rare cancer is rare by itself, it accounts for up to 15% of all newly diagnosed cancer cases when the number of each subtype of rare cancer is combined. Information on rare cancers has been lacking to date and this background makes it difficult for clinicians to diagnose rare cancer correctly and treat patients appropriately. Another problem is the lack of experienced experts in the field of rare cancers.

The Team and What We Do

 The Rare Cancer Center has been playing a central role in the management of rare cancers in the National Cancer Center (NCC).

 The mission statements of the Rare Cancer Center are as follows.

I. Establishing a vital network for diagnosis and treatment for rare cancers.

II.  Investigating the problems associated with rare cancers and taking up the issues and making proposals as medical professionals for rare cancers.

 The Rare Cancer Center provides specialized and high-quality medical care to patients with rare cancers, and promotes research on rare cancers by taking a multidisciplinary approach. Monthly regular web-conference have been held between the Tsukiji and Kashiwa campuses to discuss issues in the treatment of rare cancers.

Research activities

 A rare cancer hotline has been established to provide consultations for patients with rare cancers and their families over the telephone. The number of new consultations between April and September in 2021 was 5,023. The consulters lived from Hokkaido to Okinawa. Since October 2021, the Supportive Care Development Center has been in charge of the rare cancer hotline.

 To deliver information on rare cancers, a website for patients with rare cancers and their families (https://www.ncc.go.jp/jp/rcc/index.html) has been launched, and 350 new pieces of content were added in 2021. In addition, information is disseminated via Facebook to provide it in a timely manner, and 400 posts were made in 2021. Rare Cancer Leaflets for 50 subtypes of rare cancers were created and distributed.

 Since 2017, “Rare Cancer Meet the Expert”, a seminar on rare cancers, has been held for patients and their families. In 2021, the seminar could not be held due to COVID-19, and only video streaming was available. The total view count for all videos was 477,992. We also have prepared a “Rare Cancers Library” which consists of 15 videos for the purpose of delivering timely information to patients quickly and efficiently. This accomplished 12,183 views. We also held eight seminars on rare cancer treatment together in collaboration with six patient advocacy groups.

 We promoted Cancer Awareness Month covering four rare cancers, including mesothelioma and lymphoma, in collaboration with the patient advocacy group.

 We promoted cancer awareness month covering four rare cancers, including sarcoma and lymphoma, in collaboration with the patient advocacy group.

 In the project “Research on understanding the status of medical treatment and development of infrastructure to improve the outcomes of rare cancers” funded by the Cancer Research and Development Fund, members of the Rare Cancer Center took the leading role in conducting research on understanding the status of medical treatment for rare cancers, information dissemination, and education. Also, in the project “Research on developing a network providing cancer information and consultation support for rare cancers” funded by the Ministry of Health, Labour and Welfare Grants-in-aid for Scientific Research program, the Rare Cancer Center worked toward maintaining a network of hospitals treating rare cancers in line with the situations in each region in Japan. In 2021, the Rare Cancer Grant Program was established based on several donations to the Rare Cancer Center from people who supported its initiatives and actions. We called for applications for research funding and subsequently supported 19 researchers conducting leading-edge research at the Rare Cancer Center.

Future Prospects

 As the National Institute for Rare Cancers in Japan, our missions are to develop networks connecting patients and healthcare providers across the nation, to promote extraordinary patient care, scientific research, and education on rare cancers. Tuning into the issues faced by all rare cancer patients, we address them with a global perspective.

List of papers published in 2021

Journal

1. Yamada I, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ueno M, Ikeda M, Okano N, Todaka A, Shimizu S, Mizuno N, Sekimoto M, Tobimatsu K, Yamaguchi H, Nishina T, Shirakawa H, Kojima Y, Oono T, Kawamoto Y, Furukawa M, Iwai T, Sudo K, Okamura K, Yamashita T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J. The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113. Scientific reports, 12:987, 2022

2. Narita Y, Sato S, Kayama T. Review of the diagnosis and treatment of brain metastases. Japanese journal of clinical oncology, 52:3-7, 2022

3. Noguchi R, Yoshimatsu Y, Ono T, Sei A, Motoi N, Yatabe Y, Yoshida Y, Watanabe S, Kondo T. Establishment and characterization of NCC-DMM1-C1, a novel patient-derived cell line of desmoplastic malignant pleural mesothelioma. Oncology letters, 23:64, 2022

4. Shibayama T, Shimoi T, Mori T, Noguchi E, Honma Y, Hijioka S, Yoshida M, Ogawa C, Yonemori K, Yatabe Y, Yoshida A. Cytokeratin-positive Malignant Tumor in the Abdomen With EWSR1/FUS-CREB Fusion: A Clinicopathologic Study of 8 Cases. The American journal of surgical pathology, 46:134-146, 2022

5. Kurosawa S, Yamaguchi T, Mori A, Tsukagoshi M, Okuda I, Ikeda M, Ueno T, Saito Y, Aihara Y, Matsuba Y, Fuji S, Yamashita T, Ogawa C, Ito A, Tanaka T, Inamoto Y, Kim SW, Fukuda T. Feasibility and usefulness of recommended screenings at long-term follow-up clinics for hematopoietic cell transplant survivors. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer, 30:2767-2776, 2022

6. Takamizawa S, Morizane C, Tanabe N, Maruki Y, Kondo S, Hijioka S, Ueno H, Sugano K, Hiraoka N, Okusaka T. Clinical characteristics of pancreatic and biliary tract cancers associated with Lynch syndrome. Journal of hepato-biliary-pancreatic sciences, 29:377-384, 2022

7. Yachida S, Totoki Y, Noë M, Nakatani Y, Horie M, Kawasaki K, Nakamura H, Saito-Adachi M, Suzuki M, Takai E, Hama N, Higuchi R, Hirono S, Shiba S, Kato M, Furukawa E, Arai Y, Rokutan H, Hashimoto T, Mitsunaga S, Kanda M, Tanaka H, Takata S, Shimomura A, Oshima M, Hackeng WM, Okumura T, Okano K, Yamamoto M, Yamaue H, Morizane C, Arihiro K, Furukawa T, Sato T, Kiyono T, Brosens LAA, Wood LD, Hruban RH, Shibata T . Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System. Cancer discovery, 12:692-711, 2022

8. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Sugaya J, Nakatani F, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-UPS3-C1: a novel patient-derived cell line of undifferentiated pleomorphic sarcoma. Human cell, 35:384-391, 2022

9. Toda Y, Kobayashi E, Yoshida A, Kawai A. Gorham-Stout syndrome mimicking a malignant bone tumor in two adult cases. Japanese journal of clinical oncology, 52:197, 2022

10. Toki S, Sone M, Yoshida A, Nishisho T, Gokita T, Kobayashi E, Nakatani F, Chuman H, Sugawara S, Arai Y, Kawai A. Image-guided core needle biopsy for musculoskeletal lesions. Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association, 27:448-455, 2022

11. Yoshida A, Arai Y, Satomi K, Kubo T, Ryo E, Matsushita Y, Hama N, Sudo K, Komiyama M, Yatabe Y, Shibata T, Ichikawa H, Ichimura K, Kawai A, Mori T. Identification of novel SSX1 fusions in synovial sarcoma. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc, 35:228-239, 2022

12. Ono M, Matsumoto K, Boku N, Fujii N, Tsuchida Y, Furui T, Harada M, Kanda Y, Kawai A, Miyachi M, Murashima A, Nakayama R, Nishiyama H, Shimizu C, Sugiyama K, Takai Y, Fujio K, Morishige KI, Osuga Y, Suzuki N. Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases. International journal of clinical oncology, 27:301-309, 2022

13. Sin Y, Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Akiyama T, Nakatani F, Sugaya J, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-MPNST6-C1: a novel patient-derived cell line of malignant peripheral nerve sheath tumors. Human cell, 35:400-407, 2022

14. Kido A, Kitagawa Y, Tsukushi S, Iwata S, Ishida Y, Tsukamoto S, Kawai A. Marginal resection for patients with atypical lipomatous tumours of the extremities and trunk wall: a systematic review and meta-analysis. Japanese journal of clinical oncology, 52:151-156, 2022

15. Nakamura T, Kawai A, Sudo A. The incidence of unplanned excision in patients with soft tissue sarcoma: Reports from the Bone and Soft Tissue Tumor registry in Japan. Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association, 27:468-472, 2022

16. Nakamura T, Kawai A, Asanuma K, Hagi T, Sudo A. Is no additional excision after unplanned excision with positive margins justified in patients with small (≤5 cm) high-grade soft-tissue sarcoma?: Analysis from the Bone and Soft Tissue Tumor registry in Japan. Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association, 27:463-467, 2022

17. Arikawa M, Akazawa S, Kagaya Y, Kawai A, Miyamoto S. Free Flap Reconstruction of Oncologic Gluteal Defects. Annals of plastic surgery, 88:420-424, 2022

18. Tanabe K, Nakanishi Y, Matsumoto S, Yajima S, Kuroe T, Watanabe R, Arai Y, Iwata S, Ito M, Masuda H. Utility of a multidisciplinary team approach with transanal total mesorectal excision for resection of a large pelvic solitary fibrous tumor. IJU case reports, 5:104-107, 2022

19. Abe K, Maeda-Minami A, Ishizu T, Iwata S, Kobayashi E, Shimoi T, Kawano Y, Hashimoto H, Yamaguchi M, Furukawa T, Miyazaki S, Mano Y. Risk Factors for Hepatic Toxicity of High-dose Methotrexate in Patients With Osteosarcoma. Anticancer research, 42:1043-1050, 2022

20. COVIDSurg Collaborative, GlobalSurg Collaborative . SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. Anaesthesia, 77:28-39, 2022

21. Gogas H, Dummer R, Ascierto PA, Arance A, Mandalà M, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Chiarion Sileni V, Dutriaux C, Yamazaki N, Loquai C, Queirolo P, de Willem GJ, Sellier AT, Suissa J, Murris J, Gollerkeri A, Robert C, Flaherty KT . Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]. European journal of cancer (Oxford, England: 1990), 160:287-288, 2022

22. Saito Y, Kumamoto T, Yamaguchi M, Ogawa C, Kato M. Use of Pegfilgrastim in Japanese Pediatric Patients With Solid Tumors: A Retrospective Analysis. Journal of pediatric hematology/oncology, 44:e386-e390, 2022

23. Kawakubo N, Hishiki T, Arakawa A, Nakajima M, Kumamoto T, Nakagawa K, Kawai A, Ogawa C. Surgical Treatment for Pneumothorax and Tumor-bronchial Fistula Secondary to Pulmonary Metastasis of Osteosarcoma in Pediatric and Adolescent Patients. Journal of pediatric hematology/oncology, 2022

24. Usui Y, Miura T, Kawaguchi T, Kosugi K, Uehara Y, Kato M, Kosugi T, Sone M, Nakamura N, Mizushima A, Miyashita M, Morita T, Yamaguchi T, Matsumoto Y, Satomi E. Palliative care physicians' recognition of patients after immune checkpoint inhibitors and immune-related adverse events. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer, 30:775-784, 2022

25. Igaki H, Murakami N, Nakamura S, Yamazaki N, Kashihara T, Takahashi A, Namikawa K, Takemori M, Okamoto H, Iijima K, Chiba T, Nakayama H, Takahashi A, Kaneda T, Takahashi K, Inaba K, Okuma K, Nakayama Y, Shimada K, Nakagama H, Itami J. Scalp angiosarcoma treated with linear accelerator-based boron neutron capture therapy: A report of two patients. Clinical and translational radiation oncology, 33:128-133, 2022

26. Yoshida H, Uno M, Kato T. Bartholin's glands commonly express NKX3.1: reconsideration of “prostatic differentiation” in gynaecological pathology. Histopathology, 80:1013-1015, 2022

27. Machado, Isidro// Charville, Gregory W// Yoshida, Akihiko// Navarro, Samuel// Righi, Alberto// Gambarotti, Marco// Scotlandi, Katia// López-Guerrero, José A// Llombart-Bosch, Antonio. Does PAX7 and NKX2.2 immunoreactivity in Ewing sarcoma have prognostic significance? Virchows Archiv: an international journal of pathology, 480:909-917, 2022

28. Yoshida A, Satomi K, Kobayashi E, Ryo E, Matsushita Y, Narita Y, Ichimura K, Kawai A, Mori T. Soft-tissue sarcoma with MN1-BEND2 fusion: A case report and comparison with astroblastoma. Genes, chromosomes & cancer, 61:427-431, 2022

29. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, Noguchi M, Papotti M, Rekhtman N, Scagliotti G, van Schil P, Sholl L, Yatabe Y, Yoshida A, Travis WD. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer, 17:362-387, 2022

30. Hosoya T, Takahashi M, Honda-Kitahara M, Miyakita Y, Ohno M, Yanagisawa S, Omura T, Kawauchi D, Tamura Y, Kikuchi M, Nakano T, Yoshida A, Igaki H, Matsushita Y, Ichimura K, Narita Y. MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas. Journal of neuro-oncology, 157:561-571, 2022

31. Kawauchi D, Ohno M, Honda-Kitahara M, Miyakita Y, Takahashi M, Yanagisawa S, Tamura Y, Kikuchi M, Ichimura K, Narita Y. The clinical characteristics and outcomes of incidentally discovered glioblastoma. Journal of neuro-oncology, 156:551-557, 2022

32. Shirakihara T, Yamaguchi H, Kondo T, Yashiro M, Sakai R. Transferrin receptor 1 promotes the fibroblast growth factor receptor-mediated oncogenic potential of diffused-type gastric cancer. Oncogene, 41:2587-2596, 2022

33. Ponce RKM, Thomas NJ, Bui NQ, Kondo T, Okimoto RA. WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma. JCI insight, 7:2022

34. Sin Y, Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Akiyama T, Iwata S, Sugaya J, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Human cell, 35:936-943, 2022

35. Noguchi R, Yoshimatsu Y, Sin Y, Ono T, Tsuchiya R, Yoshida H, Kiyono T, Yonemura Y, Kondo T. Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei. Journal of personalized medicine, 12:2022

36. Ono T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Akiyama T, Sugaya J, Fukushima S, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li-Fraumeni syndrome. Human cell, 35:756-766, 2022

37. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Sugaya J, Kobayashi E, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and Characterization of NCC-MFS5-C1: A Novel Patient-Derived Cell Line of Myxofibrosarcoma. Cells, 11:2022

38. Ono T, Noguchi R, Yoshimatsu Y, Tsuchiya R, Sin Y, Nakagawa R, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone. Human cell, 35:392-399, 2022

39. Ueno M, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ikeda M, Ozaka M, Okano N, Sugimori K, Todaka A, Shimizu S, Mizuno N, Yamamoto T, Sano K, Tobimatsu K, Katanuma A, Miyamoto A, Yamaguchi H, Nishina T, Shirakawa H, Kojima Y, Oono T, Kawamoto Y, Furukawa M, Iwai T, Sudo K, Miyakawa H, Yamashita T, Yasuda I, Takahashi H, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J. Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113. Scientific reports, 11:12885, 2021

40. Arakawa Y, Sasaki K, Mineharu Y, Uto M, Mizowaki T, Mizusawa J, Sekino Y, Ono T, Aoyama H, Satomi K, Ichimura K, Kinoshita M, Ohno M, Ito Y, Nishikawa R, Fukuda H, Nishimura Y, Narita Y. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). BMC cancer, 21:1105, 2021

41. Fujimoto K, Arita H, Satomi K, Yamasaki K, Matsushita Y, Nakamura T, Miyakita Y, Umehara T, Kobayashi K, Tamura K, Tanaka S, Higuchi F, Okita Y, Kanemura Y, Fukai J, Sakamoto D, Uda T, Machida R, Kuchiba A, Maehara T, Nagane M, Nishikawa R, Suzuki H, Shibuya M, Komori T, Narita Y, Ichimura K. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta neuropathologica, 142:323-338, 2021

42. Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro-oncology, 23:122-133, 2021

43. Narita Y, Muragaki Y, Kagawa N, Asai K, Nagane M, Matsuda M, Ueki K, Kuroda J, Date I, Kobayashi H, Kumabe T, Beppu T, Kanamori M, Kasai S, Nishimura Y, Xiong H, Ocampo C, Yamada M, Mishima K. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. Cancer science, 112:5020-5033, 2021

44. Ohno M, Hayashi Y, Aikawa H, Hayashi M, Miyakita Y, Takahashi M, Matsushita Y, Yoshida A, Satomi K, Ichimura K, Hamada A, Narita Y. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas. Neurology, 97:e2114-e2123, 2021

45. Yonezawa H, Ohno M, Igaki H, Miyakita Y, Takahashi M, Tamura Y, Shima S, Matsushita Y, Ichimura K, Narita Y. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*. Japanese journal of clinical oncology, 51:1028-1035, 2021

46. Aoki T, Kagawa N, Sugiyama K, Wakabayashi T, Arakawa Y, Yamaguchi S, Tanaka S, Ishikawa E, Muragaki Y, Nagane M, Nakada M, Suehiro S, Hata N, Kuroda J, Narita Y, Sonoda Y, Iwadate Y, Natsumeda M, Nakazato Y, Minami H, Hirata Y, Hagihara S, Nishikawa R. Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study. International journal of clinical oncology, 26:2205-2215, 2021

47. Oort Q, Dirven L, Sikkes SAM, Aaronson N, Boele F, Brannan C, Egeter J, Grant R, Klein M, Lips I, Narita Y, Sato H, Sztankay M, Stockhammer G, Talacchi A, Uitdehaag BMJ, Reijneveld JC, Taphoorn MJB . Development of an EORTC questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumours: phase I-III. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation, 30:1491-1502, 2021

48. Kawaguchi RK, Takahashi M, Miyake M, Kinoshita M, Takahashi S, Ichimura K, Hamamoto R, Narita Y, Sese J. Assessing Versatile Machine Learning Models for Glioma Radiogenomic Studies across Hospitals. Cancers, 13:2021

49. Kanamori M, Takami H, Suzuki T, Tominaga T, Kurihara J, Tanaka S, Hatazaki S, Nagane M, Matsuda M, Yoshino A, Natsumeda M, Yamaoka M, Kagawa N, Akiyama Y, Fukai J, Negoto T, Shibahara I, Tanaka K, Inoue A, Mase M, Tomita T, Kuga D, Kijima N, Fukami T, Nakahara Y, Natsume A, Yoshimoto K, Keino D, Tokuyama T, Asano K, Ujifuku K, Abe H, Nakada M, Matsuda KI, Arakawa Y, Ikeda N, Narita Y, Shinojima N, Kambe A, Nonaka M, Izumoto S, Kawanishi Y, Kanaya K, Nomura S, Nakajima K, Yamamoto S, Terashima K, Ichimura K, Nishikawa R. Necessity for craniospinal irradiation of germinoma with positive cytology without spinal lesion on MR imaging-A controversy. Neuro-oncology advances, 3:vdab086, 2021

50. Oya S, Ikawa F, Ichihara N, Wanibuchi M, Akiyama Y, Nakatomi H, Mikuni N, Narita Y. Nation-wide Brain Tumor Registry-based Study of Intracranial Meningioma in Japan: Analysis of Surgery-related Risks. Neurologia medico-chirurgica, 61:98-106, 2021

51. Takahashi S, Takahashi M, Tanaka S, Takayanagi S, Takami H, Yamazawa E, Nambu S, Miyake M, Satomi K, Ichimura K, Narita Y, Hamamoto R. A New Era of Neuro-Oncology Research Pioneered by Multi-Omics Analysis and Machine Learning. Biomolecules, 11:2021

52. Takami H, Graffeo CS, Perry A, Ohno M, Ishida J, Giannini C, Narita Y, Nakazato Y, Saito N, Nishikawa R, Matsutani M, Ichimura K, Daniels DJ. Histopathology and prognosis of germ cell tumors metastatic to brain: cohort study. Journal of neuro-oncology, 154:121-130, 2021

53. Takami H, Satomi K, Fukuoka K, Fukushima S, Matsushita Y, Yamasaki K, Nakamura T, Tanaka S, Mukasa A, Saito N, Suzuki T, Yanagisawa T, Nakamura H, Sugiyama K, Tamura K, Maehara T, Nakada M, Nonaka M, Asai A, Yokogami K, Takeshima H, Iuchi T, Kanemura Y, Kobayashi K, Nagane M, Kurozumi K, Yoshimoto K, Matsuda M, Matsumura A, Hirose Y, Tokuyama T, Kumabe T, Narita Y, Shibui S, Nakazato Y, Nishikawa R, Matsutani M, Ichimura K. Low tumor cell content predicts favorable prognosis in germinoma patients. Neuro-oncology advances, 3:vdab110, 2021

54. Wakabayashi T, Hirose Y, Miyake K, Arakawa Y, Kagawa N, Nariai T, Narita Y, Nishikawa R, Tsuyuguchi N, Fukami T, Sasaki H, Sasayama T, Kondo A, Iuchi T, Matsuda H, Kubota K, Minamimoto R, Terauchi T, Nakazato Y, Kubomura K, Wada M. Determining the extent of tumor resection at surgical planning with 18F-fluciclovine PET/CT in patients with suspected glioma: multicenter phase III trials. Annals of nuclear medicine, 35:1279-1292, 2021

55. Yamagishi Y, Sasaki N, Nakano Y, Matushita Y, Omura T, Shimizu S, Saito K, Kobayashi K, Narita Y, Kondo A, Shiokawa Y, Nagane M, Ichimura K. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma. Cancer science, 112:4702-4710, 2021

56. Yamamuro S, Takahashi M, Satomi K, Sasaki N, Kobayashi T, Uchida E, Kawauchi D, Nakano T, Fujii T, Narita Y, Kondo A, Wada K, Yoshino A, Ichimura K, Tomiyama A. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. Cancer science, 112:4736-4747, 2021

57. Yazaki S, Yoshida T, Kojima Y, Yagishita S, Nakahama H, Okinaka K, Matsushita H, Shiotsuka M, Kobayashi O, Iwata S, Narita Y, Ohba A, Takahashi M, Iwasa S, Kobayashi K, Ohe Y, Yoshida T, Hamada A, Doi T, Yamamoto N. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan. JAMA oncology, 7:1141-1148, 2021

58. Shiga K, Nibu KI, Fujimoto Y, Asakage T, Homma A, Mitani H, Ogawa T, Okami K, Murono S, Hirano S, Ueda T, Hanai N, Tsukahara K, Ota I, Yoshimoto S, Shinozaki T, Iwae S, Katagiri K, Saito D, Kiyota N, Tahara M, Takahashi F, Hayashi R. Sites of invasion of cancer of the external auditory canal predicting oncologic outcomes. Head & neck, 43:3097-3105, 2021

59. Eguchi K, Kobayashi K, Takano T, Ito A, Sakai A, Ikeda A, Matsumoto Y, Omura G, Matsumoto F, Yoshimoto S. Carotid artery ligation via sternotomy as a palliative surgery: Case report of advanced intramediastinal malignant soft tissue tumor. Clinical case reports, 9:2021

60. Hijioka S, Morizane C, Ikeda M, Ishii H, Okusaka T, Furuse J. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Japanese journal of clinical oncology, 51:1185-1196, 2021

61. Aoki T, Kubota K, Kiritani S, Arita J, Morizane C, Masui T, Kudo A, Komoto I, Hatano E, Ito T, Osamura RY, Unno M, Uemoto S, Kokudo N. Survey of surgical resections for neuroendocrine liver metastases: A project study of the Japan Neuroendocrine Tumor Society (JNETS). Journal of hepato-biliary-pancreatic sciences, 28:489-497, 2021

62. Sugawara S, Sone M, Itou C, Kimura S, Kusumoto M, Kato T, Yonemori K, Yatabe Y, Arai Y. Analysis of factors affecting the diagnostic yield of image-guided percutaneous core needle biopsy for peritoneal/omental lesions. Abdominal radiology (New York), 46:4499-4508, 2021

63. Stacchiotti S, Miah AB, Frezza AM, Messiou C, Morosi C, Caraceni A, Antonescu CR, Bajpai J, Baldini E, Bauer S, Biagini R, Bielack S, Blay JY, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Callegaro D, De Alava E, Deoras-Sutliff M, Dufresne A, Eriksson M, Errani C, Fedenko A, Ferraresi V, Ferrari A, Fletcher CDM, Garcia Del Muro X, Gelderblom H, Gladdy RA, Gouin F, Grignani G, Gutkovich J, Haas R, Hindi N, Hohenberger P, Huang P, Joensuu H, Jones RL, Jungels C, Kasper B, Kawai A, Le Cesne A, Le Grange F, Leithner A, Leonard H, Lopez Pousa A, Martin Broto J, Merimsky O, Merriam P, Miceli R, Mir O, Molinari M, Montemurro M, Oldani G, Palmerini E, Pantaleo MA, Patel S, Piperno-Neumann S, Raut CP, Ravi V, Razak ARA, Reichardt P, Rubin BP, Rutkowski P, Safwat AA, Sangalli C, Sapisochin G, Sbaraglia M, Scheipl S, Schöffski P, Strauss D, Strauss SJ, Sundby Hall K, Tap WD, Trama A, Tweddle A, van der Graaf WTA, Van De Sande MAJ, Van Houdt W, van Oortmerssen G, Wagner AJ, Wartenberg M, Wood J, Zaffaroni N, Zimmermann C, Casali PG, Dei Tos AP, Gronchi A . Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO open, 6:100170, 2021

64. Yoshimatsu Y, Noguchi R, Tsuchiya R, Sin Y, Ono T, Sugaya J, Iwata S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma. Human cell, 34:1911-1918, 2021

65. Chen TW, Pang A, Puhaindran ME, Maw MM, Loong HH, Sriuranpong V, Chang CC, Mingmalairak S, Hirose T, Endo M, Kawai A, Farid M, Tan SH, Goh WL, Quek R, Chan JCH, Leung AKC, Ngan RKC. The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium. Cancer science, 112:1095-1104, 2021

66. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Sei A, Takeshita F, Sugaya J, Nakatani F, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-ssRMS2-C1: a novel patient-derived cell line of spindle cell/sclerosing rhabdomyosarcoma. Human cell, 34:1569-1578, 2021

67. Nakagawa M, Kobayashi E, Yamada M, Watanabe T, Hirata M, Tanabe N, Ushiama M, Sakamoto H, Sato C, Mori T, Yoshida A, Yoshida T, Sugano K, Kawai A. Myxofibrosarcoma harboring an MLH1 pathogenic germline variant associated with Muir-Torre syndrome: a case report. Hereditary cancer in clinical practice, 19:34, 2021

68. Kawai A, Naka N, Shimomura A, Takahashi S, Kitano S, Imura Y, Yonemori K, Nakatani F, Iwata S, Kobayashi E, Outani H, Tamiya H, Naito Y, Yamamoto N, Doi T. Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study. Investigational new drugs, 39:1559-1567, 2021

69. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Sei A, Takeshita F, Sugaya J, Iwata S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma. Human cell, 34:1266-1273, 2021

70. Kohama I, Asano N, Matsuzaki J, Yamamoto Y, Yamamoto T, Takahashi RU, Kobayashi E, Takizawa S, Sakamoto H, Kato K, Fujimoto H, Chikuda H, Kawai A, Ochiya T. Comprehensive serum and tissue microRNA profiling in dedifferentiated liposarcoma. Oncology letters, 22:623, 2021

71. Nakamura T, Kawai A, Asanuma K, Hagi T, Sudo A. Clinical Outcome of Dermatofibrosarcoma Protuberance. Report From the Bone and Soft Tissue Tumor (BSTT) Registry in Japan. In vivo (Athens, Greece), 35:611-615, 2021

72. Frezza AM, Ravi V, Lo Vullo S, Vincenzi B, Tolomeo F, Chen TW, Teterycz P, Baldi GG, Italiano A, Penel N, Brunello A, Duffaud F, Hindi N, Iwata S, Smrke A, Fedenko A, Gelderblom H, Van Der Graaf W, Vozy A, Connolly E, Grassi M, Benjamin RS, Broto JM, Grignani G, Jones RL, Kawai A, Tysarowski A, Mariani L, Casali PG, Stacchiotti S. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer medicine, 10:2645-2659, 2021

73. Nakagawa M, Sekimizu M, Endo M, Kobayashi E, Iwata S, Fukushima S, Yoshida A, Kitabayashi I, Ichikawa H, Kawai A, Nakatani F. Prognostic impact of IDH mutations in chondrosarcoma. Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association, 2021

74. Iwata S, Kawai A, Ueda T, Ishii T. Symptomatic Venous Thromboembolism in Patients with Malignant Bone and Soft Tissue Tumors: A Prospective Multicenter Cohort Study. Annals of surgical oncology, 28:3919-3927, 2021

75. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Hirose T, Iwata S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma. Journal of personalized medicine, 11:2021

76. Zhang L, Akiyama T, Fukushima T, Iwata S, Takeshita K, Kawai A, Tanaka S, Kobayashi H. Surgical resection of the primary lesion for osteosarcoma patients with metastasis at initial diagnosis. Japanese journal of clinical oncology, 51:416-423, 2021

77. Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A . Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 127:2934-2942, 2021

78. Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Sei A, Sugaya J, Iwata S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-LGFMS1-C1: a novel patient-derived cell line of low-grade fibromyxoid sarcoma. Human cell, 34:1919-1928, 2021

79. Nakamura T, Kawai A, Hagi T, Asanuma K, Sudo A. A comparison of clinical outcomes between additional excision after unplanned and planned excisions in patients with soft-tissue sarcoma of the limb: a propensity matching cohort study. The bone & joint journal, 103-B:1809-1814, 2021

80. Hagiwara Y, Iwata S, Ogura K, Kawai A, Susa M, Morioka H, Hiruma T, Tsuda Y, Kawano H, Yonemoto T, Ishii T, Okazaki K. Clinical analysis of multimodal treatment for localized synovial sarcoma: A multicenter retrospective study. Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association, 2021

81. Xu G, Aiba H, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Higuchi T, Abe K, Taniguchi Y, Araki Y, Saito S, Yoshimura K, Murakami H, Tsuchiya H, Kawai A. Efficacy of perioperative chemotherapy for synovial sarcoma: a retrospective analysis of a Nationwide database in Japan. BMC cancer, 21:773, 2021

82. Fukushima T, Ogura K, Akiyama T, Takeshita K, Kawai A. Soft tissue sarcoma in adolescent and young adult patients: a retrospective study using a nationwide bone and soft tissue tumor registry in Japan. Japanese journal of clinical oncology, 51:1080-1087, 2021

83. Nishida Y, Urakawa H, Nakayama R, Kobayashi E, Ozaki T, Ae K, Matsumoto Y, Tsuchiya H, Goto T, Hiraga H, Naka N, Takahashi S, Ando Y, Ando M, Kuwatsuka Y, Hamada S, Ueda T, Kawai A. Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors. International journal of cancer, 148:140-149, 2021

84. Hayashi K, Hiraoka K, Akiyama T, Iwata S, Tsuchiya H, Kawai A. Benefit of surgical resection of distant metastasis in soft tissue sarcoma: a systematic review. Japanese journal of clinical oncology, 51:1088-1093, 2021

85. Nakamura T, Saito Y, Tsuchiya K, Miyachi M, Iwata S, Sudo A, Kawai A. Is perioperative chemotherapy recommended in childhood and adolescent patients with synovial sarcoma? A systematic review. Japanese journal of clinical oncology, 51:927-931, 2021

86. Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Sin Y, Akane S, Sugaya J, Mori T, Fukushima S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone. Human cell, 34:1899-1910, 2021

87. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, De Álava E, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss S, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Casali PG, Stacchiotti S . Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆). Annals of oncology: official journal of the European Society for Medical Oncology, 32:1348-1365, 2021

88. Zhang L, Akiyama T, Fukushima T, Iwata S, Tsuda Y, Takeshita K, Kawai A, Tanaka S, Kobayashi H. Prognostic factors and impact of surgery in patients with metastatic soft tissue sarcoma at diagnosis: A population-based cohort study. Japanese journal of clinical oncology, 51:918-926, 2021

89. Nagano A, Tsugita M, Nishimoto Y, Akiyama H, Kawai A. The 'other' bone sarcomas in Japan: a retrospective study of primary bone sarcomas other than osteosarcoma, Ewing sarcoma and chondrosarcoma, using data from the Bone Tumuor Registry in Japan. Japanese journal of clinical oncology, 51:1430-1436, 2021

90. Fukushima T, Tsuji T, Watanabe N, Sakurai T, Matsuoka A, Kojima K, Yahiro S, Oki M, Okita Y, Yokota S, Nakano J, Sugihara S, Sato H, Kawakami J, Kagaya H, Tanuma A, Sekine R, Mori K, Zenda S, Kawai A. The current status of inpatient cancer rehabilitation provided by designated cancer hospitals in Japan. Japanese journal of clinical oncology, 51:1094-1099, 2021

91. Takenaka S, Tamiya H, Wakamatsu T, Nakai S, Imura Y, Outani H, Yagi T, Kawai A. Impact of Surgical Resection and Reasons for Poor Prognosis of Pelvic Osteosarcoma Based on the Bone Tumor Registry in Japan. Cancers, 13:2021

92. Emori M, Iba K, Murahashi Y, Shimizu J, Sonoda T, Wada T, Yamashita T, Kawai A. Oncological and prognostic analysis of soft tissue sarcoma of the elbow: report using the bone and soft tissue tumor registry in Japan. Japanese journal of clinical oncology, 51:1608-1614, 2021

93. Jones RL, Wagner AJ, Kawai A, Tamura K, Shahir A, Van Tine BA, Martín-Broto J, Peterson PM, Wright J, Tap WD . Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clinical cancer research: an official journal of the American Association for Cancer Research, 27:3861-3866, 2021

94. Brohl AS, Sindiri S, Wei JS, Milewski D, Chou HC, Song YK, Wen X, Kumar J, Reardon HV, Mudunuri US, Collins JR, Nagaraj S, Gangalapudi V, Tyagi M, Zhu YJ, Masih KE, Yohe ME, Shern JF, Qi Y, Guha U, Catchpoole D, Orentas RJ, Kuznetsov IB, Llosa NJ, Ligon JA, Turpin BK, Leino DG, Iwata S, Andrulis IL, Wunder JS, Toledo SRC, Meltzer PS, Lau C, Teicher BA, Magnan H, Ladanyi M, Khan J. Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. Cell reports, 37:110047, 2021

95. Iwata S, Tatsumi Y, Yonemoto T, Araki A, Itami M, Kamoda H, Tsukanishi T, Hagiwara Y, Kinoshita H, Ishii T, Nagase H, Ohira M. CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcoma. Oncology reports, 46:2021

96. Yokoo S, Fujiwara T, Yoshida A, Uotani K, Morita T, Kiyono M, Hasei J, Nakata E, Kunisada T, Iwata S, Yonemoto T, Ueda K, Ozaki T. Liquid Biopsy Targeting Monocarboxylate Transporter 1 on the Surface Membrane of Tumor-Derived Extracellular Vesicles from Synovial Sarcoma. Cancers, 13:2021

97. COVIDSurg Collaborative. Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study. Anaesthesia, 76:1454-1464, 2021

98. Mizuta H, Nakano E, Yamazaki N. Primary Cutaneous Rosai-Dorfman Disease of the Scalp. Dermatology practical & conceptual, 11:e2020086, 2021

99. Mizuta H, Namikawa K, Takahashi A, Ogata D, Muto Y, Jinnai S, Nakama K, Tsutsui K, Yamazaki N. The first case of a collision tumor of melanotrichoblastoma and seborrheic keratosis. International journal of dermatology, 60:e54-e56, 2021

100. Ding Z, Ogata D, Roszik J, Qin Y, Kim SH, Tetzlaff MT, Lazar AJ, Davies MA, Ekmekcioglu S, Grimm EA. iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. Frontiers in oncology, 11:631766, 2021

101. Mizuta H, Namikawa K, Nakama K, Yamazaki N. Intramedullary spinal cord metastasis of malignant melanoma:Two cases with rim signs in contrast-enhanced magnetic resonance imaging: A case report. Molecular and clinical oncology, 14:47, 2021

102. Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RN. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer medicine, 10:2293-2299, 2021

103. Uhara H, Kiyohara Y, Uehara J, Fujisawa Y, Takenouchi T, Otsuka M, Uchi H, Fukushima S, Minami H, Hatsumichi M, Yamazaki N. Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. The Journal of dermatology, 48:592-599, 2021

104. Ogata D, Namikawa K, Takahashi A, Yamazaki N. A review of the AJCC melanoma staging system in the TNM classification (eighth edition). Japanese journal of clinical oncology, 51:671-674, 2021

105. Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM . Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet. Oncology, 22:655-664, 2021

106. Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C . Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. The Lancet. Oncology, 22:643-654, 2021

107. Muto Y, Ryo E, Namikawa K, Takahashi A, Ogata D, Fujimura T, Yatabe Y, Aiba S, Yamazaki N, Mori T. RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma. Pathology international, 71:337-347, 2021

108. Yamazaki N, Takenouchi T, Nakamura Y, Takahashi A, Namikawa K, Kitano S, Fujita T, Kubota K, Yamanaka T, Kawakami Y. Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study). Japanese journal of clinical oncology, 51:1232-1241, 2021

109. Gogas H, Dummer R, Ascierto PA, Arance A, Mandalà M, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Sileni VC, Dutriaux C, Yamazaki N, Loquai C, Queirolo P, Jan de Willem G, Sellier AT, Suissa J, Murris J, Gollerkeri A, Robert C, Flaherty KT . Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). European journal of cancer (Oxford, England: 1990), 152:116-128, 2021

110. Nakama K, Ogata D, Nakano E, Tsutsui K, Jinnai S, Namikawa K, Takahashi A, Yamazaki N. Clinical response to a MEK inhibitor in a patient with metastatic melanoma harboring an RAF1 gene rearrangement detected by cancer gene panel testing. The Journal of dermatology, 48:e256-e257, 2021

111. Ishiguro A, Ogata D, Namikawa K, Takahashi A, Yamazaki N. Two cases of advanced cutaneous squamous cell carcinoma lesions on the head and neck successfully treated with nivolumab. The Journal of dermatology, 48:e434-e435, 2021

112. Umeda Y, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Onuma T, Kuwatsuka Y, Fujimoto N, Kaneko T, Onishi M, Namikawa K, Yamazaki N, Nakamura Y. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study. European journal of cancer (Oxford, England: 1990), 157:361-372, 2021

113. Ogata D, Tanese K, Nakamura Y, Otsuka M, Namikawa K, Funakoshi T, Yoshikawa S, Tsutsui K, Nakama K, Jinnai S, Kiyohara Y, Takahashi A, Yamazaki N. Impact of the changes in the completion lymph node dissection criteria and approval of adjuvant therapies on the real-world outcomes of Japanese stage III melanoma patients. International journal of clinical oncology, 26:2338-2346, 2021

114. Eggermont AM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV, Barrow C, Di Giacomo AM, Fisher R, Sandhu S, Kudchadkar R, Ortiz Romero PL, Svane IM, Larkin J, Puig S, Hersey P, Quaglino P, Queirolo P, Stroyakovskiy D, Bastholt L, Mohr P, Hernberg M, Chiarion-Sileni V, Strother M, Hauschild A, Yamazaki N, van Akkooi AC, Lorigan P, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European journal of cancer (Oxford, England: 1990), 158:156-168, 2021

115. Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Fujimoto N, Kuwatsuka Y, Onishi M, Kaneko T, Onuma T, Umeda Y, Ogata D, Takahashi A, Otsuka M, Teramoto Y, Yamazaki N. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO open, 6:100325, 2021

116. Ito Y, Maeshima AM, Hatta S, Saito Y, Fujino T, Makita S, Fukuhara S, Munakata W, Taniguchi H, Suzuki T, Maruyama D, Sone M, Izutsu K. Use of Core-Needle Biopsy for the Diagnosis of Malignant Lymphomas in Clinical Practice. Acta haematologica, 144:641-648, 2021

117. Kurosawa S, Yamaguchi T, Mori A, Tsukagoshi M, Okuda I, Ikeda M, Fuji S, Yamashita T, Ogawa C, Ito A, Tanaka T, Inamoto Y, Kim SW, Fukuda T. Prognostic Impact of Pretransplantation Quality of Life and Its Post-Transplantation Longitudinal Change after Allogeneic Hematopoietic Cell Transplantation: A Prospective Study That Administered the Short-Form Health Survey (SF-12) and EuroQol 5. Transplantation and cellular therapy, 27:935.e1-935.e9, 2021

118. Lissat A, van Schewick C, Steffen IG, Arakawa A, Bourquin JP, Burkhardt B, Henze G, Mann G, Peters C, Sramkova L, Eckert C, von Stackelberg A, Chen-Santel C. Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma-A Report from the ALL-REZ Study Group. Journal of clinical medicine, 10:2021

119. Koretsune Y, Sone M, Arai Y, Sugawara S, Itou C, Kimura S, Kusumoto M. Feasibility and Safety of the Craniocaudal Approach for Superior Sulcus Lesions of the Thorax. Cardiovascular and interventional radiology, 44:1456-1461, 2021

120. Itou C, Arai Y, Sone M, Sugawara S, Onishi Y, Kimura S. Transgastric Feeding Tube Insertion into the Jejunum after Esophagectomy: Direct Puncture of the Gastric Conduit. Journal of vascular and interventional radiology: JVIR, 32:1464-1469, 2021

121. Wada S, Arai Y, Sone M, Sugawara S, Itou C. The value of angio-CT system on splanchnic nerve neurolysis. Diagnostic and interventional radiology (Ankara, Turkey), 27:408-412, 2021

122. Dermawan JK, Azzato EM, Billings SD, Fritchie KJ, Aubert S, Bahrami A, Barisella M, Baumhoer D, Blum V, Bode B, Aesif SW, Bovée JVMG, Dickson BC, van den Hout M, Lucas DR, Moch H, Oaxaca G, Righi A, Sciot R, Sumathi V, Yoshida A, Rubin BP . YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc, 34:2211-2221, 2021

123. Makise N, Mori T, Motoi T, Shibahara J, Ushiku T, Yoshida A. Recurrent FOS rearrangement in proliferative fasciitis/proliferative myositis. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc, 34:942-950, 2021

124. Makise N, Yoshida KI, Iijima T, Yoshida A, Ushiku T, Ishida T. Skeletal EWSR1-NFATC2 sarcoma previously diagnosed as Ewing-like adamantinoma: A case report and literature review emphasizing its unique radiological features. Pathology international, 71:614-620, 2021

125. Yoshida A, Hashimoto T, Ryo E, Yoshida KI, Motoi T, Yatabe Y, Mori T. Confirmation of NKX3-1 Expression in EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma Using Monoclonal Antibody Immunohistochemistry, RT-PCR, and RNA In Situ Hybridization. The American journal of surgical pathology, 45:578-582, 2021

126. Yoshida A. Osteosarcoma: Old and New Challenges. Surgical pathology clinics, 14:567-583, 2021

127. Ono T, Noguchi R, Yoshimatsu Y, Sin Y, Kojima N, Kondo T. Development of different organ derived decellularized tissue gels that support in vitro tumor cell behavior in a tumor type-specific manner. Journal of Electrophoresis, 65:33-37, 2021

128. Komatsu A, Matsumoto K, Yoshimatsu Y, Sin Y, Kubota A, Saito T, Mizumoto A, Ohashi S, Muto M, Noguchi R, Kondo T, Tamanoi F. The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine. Cells, 10:2021

129. Yamawaki K, Mori Y, Sakai H, Kanda Y, Shiokawa D, Ueda H, Ishiguro T, Yoshihara K, Nagasaka K, Onda T, Kato T, Kondo T, Enomoto T, Okamoto K. Integrative analyses of gene expression and chemosensitivity of patient-derived ovarian cancer spheroids link G6PD-driven redox metabolism to cisplatin chemoresistance. Cancer letters, 521:29-38, 2021

130. DeSalvo J, Ban Y, Li L, Sun X, Jiang Z, Kerr DA, Khanlari M, Boulina M, Capecchi MR, Partanen JM, Chen L, Kondo T, Ornitz DM, Trent JC, Eid JE. ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control. The Journal of clinical investigation, 131:2021

131. Takamizawa Y, Shida D, Horie T, Tsukamoto, Esaki M, Shimada K, Kondo T, Kanemitsu Y. Prognostic Role for Primary Tumor Location in Patients with Colorectal Liver Metastases: A Comparison of Right-Sided Colon, Left-Sided Colon, and Rectum. Diseases of the colon and rectum, 2021

132. Noguchi R, Yoshimatsu Y, Sei A, Yoshida H, Katou T, Kondo T. Drug screening and kinase activity profiling of a novel patient-derived cell line of clear cell ovarian carcinoma. Journal of Electrophoresis, 65:23-31, 2021

133. Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma. Human cell, 34:990-997, 2021

134. Kawauchi D, Takahashi M, Satomi K, Yamamuro S, Kobayashi T, Uchida E, Honda-Kitahara M, Narita Y, Iwadate Y, Ichimura K, Tomiyama A. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death. Cancer science, 112:2442-2453, 2021

135. Satomi K, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Narita Y, Ichimura K, Yoshida A. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc, 34:688-700, 2021

136. Matsumoto F, Miyakita Y, Sakai A, Akamatsu M, Matsumoto Y, Matsumura S, Omura G, Kobayashi K, Narita Y, Yoshimoto S. Resection of carcinoma of the external auditory canal in a patient with a high jugular bulb using temporal craniotomy. Auris, nasus, larynx, 48:535-538, 2021

137. Ozawa T, Kaneko S, Szulzewsky F, Qiao Z, Takadera M, Narita Y, Kondo T, Holland EC, Hamamoto R, Ichimura K. C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation. Acta neuropathologica communications, 9:36, 2021

138. Takahashi S, Takahashi M, Kinoshita M, Miyake M, Kawaguchi R, Shinojima N, Mukasa A, Saito K, Nagane M, Otani R, Higuchi F, Tanaka S, Hata N, Tamura K, Tateishi K, Nishikawa R, Arita H, Nonaka M, Uda T, Fukai J, Okita Y, Tsuyuguchi N, Kanemura Y, Kobayashi K, Sese J, Ichimura K, Narita Y, Hamamoto R. Fine-Tuning Approach for Segmentation of Gliomas in Brain Magnetic Resonance Images with a Machine Learning Method to Normalize Image Differences among Facilities. Cancers, 13:2021

139. Shibayama T, Makise N, Motoi T, Mori T, Hiraoka N, Yonemori K, Watanabe SI, Esaki M, Morizane C, Okuma T, Kawai A, Ushiku T, Yatabe Y, Yoshida A. Clinicopathologic Characterization of Epithelioid Hemangioendothelioma in a Series of 62 Cases: A Proposal of Risk Stratification and Identification of a Synaptophysin-positive Aggressive Subset. The American journal of surgical pathology, 45:616-626, 2021

140. Umeda K, Miyamura T, Yamada K, Sano H, Hosono A, Sumi M, Okita H, Kumamoto T, Kawai A, Hirayama J, Jyoko R, Sawada A, Nakayama H, Hosoya Y, Maeda N, Yamamoto N, Imai C, Hasegawa D, Chin M, Ozaki T. Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group. Cancer reports (Hoboken, N.J.), 4:e1329, 2021

141. Kohsaka S, Hirata M, Ikegami M, Ueno T, Kojima S, Sakai T, Ito K, Naka N, Ogura K, Kawai A, Iwata S, Okuma T, Yonemoto T, Kobayashi H, Suehara Y, Hiraga H, Kawamoto T, Motoi T, Oda Y, Matsubara D, Matsuda K, Nishida Y, Mano H. Comprehensive molecular and clinicopathological profiling of desmoid tumours. European journal of cancer (Oxford, England: 1990), 145:109-120, 2021

142. Hirozane T, Masuda M, Sugano T, Sekita T, Goto N, Aoyama T, Sakagami T, Uno Y, Moriyama H, Sawa M, Asano N, Nakamura M, Matsumoto M, Nakayama R, Kondo T, Kawai A, Kobayashi E, Yamada T. Direct conversion of osteosarcoma to adipocytes by targeting TNIK. JCI insight, 6:2021

143. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sei A, Takeshita F, Sugaya J, Fukushima S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Human cell, 34:260-270, 2021

144. Tsuchiya R, Yoshimatsu Y, Noguchi R, Ono T, Sei A, Takeshita F, Sugaya J, Fukushima S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Human cell, 34:1008-1018, 2021

145. Tsuchiya R, Yoshimatsu Y, Noguchi R, Ono T, Sei A, Takeshita F, Sugaya J, Iwata S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-SS4-C1: a novel patient-derived cell line of synovial sarcoma. Human cell, 34:998-1007, 2021

146. Kim Y, Kobayashi E, Suehara Y, Ito A, Kubota D, Tanzawa Y, Endo M, Nakatani F, Nakatsura T, Kawai A, Kaneko K, Kitano S. Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma. Oncology letters, 21:212, 2021

147. Wada S, Sadahiro R, Matsuoka YJ, Uchitomi Y, Yamaguchi T, Sato T, Shimada K, Yoshimoto S, Daiko H, Kanemitsu Y, Kawai A, Kato T, Fujimoto H, Shimizu K. Yokukansan for Treatment of Preoperative Anxiety and Prevention of Postoperative Delirium in Cancer Patients Undergoing Highly Invasive Surgery. J-SUPPORT 1605 (ProD Study): A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of pain and symptom management, 61:71-80, 2021

148. Tsutsui K, Namikawa K, Mori T, Kato K, Jinnai S, Nakama K, Ogata D, Takahashi A, Yamazaki N. Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer. The Journal of dermatology, 48:e114-e115, 2021

149. Takeyasu Y, Okuma HS, Kojima Y, Nishikawa T, Tanioka M, Sudo K, Shimoi T, Noguchi E, Arakawa A, Mori T, Sunami K, Kubo T, Kohno T, Akihiko Y, Yamamoto N, Yonemori K. Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors. JCO precision oncology, 5:2021

150. Onishi Y, Kusumoto M, Motoi N, Hiraoka N, Sugawara S, Itou C, Sone M. Natural History of Epithelioid Hemangioendothelioma of the Liver: CT Findings of 15 Cases. Academic radiology, 28:778-782, 2021

151.Hamoya T, Fujii G, Iizumi Y, Narita T, Komiya M, Matsuzawa Y, Miki K, Kondo T, Kishimoto S, Watanabe K, Wakabayashi K, Sakai T, Toshima J, Mutoh M. Artesunate inhibits intestinal tumorigenesis through inhibiting wnt signaling. Carcinogenesis, 42:148-158, 2021

152. Shiga K, Nibu KI, Fujimoto Y, Asakage T, Homma A, Mitani H, Ogawa T, Okami K, Murono S, Hirano S, Ueda T, Hanai N, Tsukahara K, Ota I, Yoshimoto S, Shinozaki T, Iwae S, Katagiri K, Saito D, Kiyota N, Tahara M, Takahashi F, Hayashi R. Multi-institutional Survey of Squamous Cell Carcinoma of the External Auditory Canal in Japan. The Laryngoscope, 131:E870-E874, 2021

153. Kimura T, Kawai K, Kandori S, Nitta S, Kojo K, Nagumo Y, Negoro H, Okuyama A, Higashi T, Kojima T, Nishiyama H. Impact of centralization in primary retroperitoneal sarcoma treatment: analysis using hospital-based cancer registry data in Japan. International journal of clinical oncology, 25:1687-1694, 2020